Marvel Biosciences Corp AI Stock Analysis
Want to see TSE:MRVL full AI Analyst Report?
Marvel Biosciences Corp (MRVL) AI Stock Analysis
Marvel Biosciences Corp
(TSXV:MRVL)
The overall score is held down primarily by very weak financial fundamentals—no revenue, sustained losses, negative equity, and ongoing cash burn—leaving the company highly dependent on external financing and future trial or commercialization milestones. Valuation adds further risk because investors are paying for a speculative pipeline without support from earnings or dividends, so downside is meaningful if development progress disappoints. These negatives are partially offset by neutral‑to‑slightly positive technicals, which indicate some recent price stabilization and mild upward bias but no strong momentum trend to materially improve the risk‑reward profile.
Marvel Biosciences Corp (MRVL) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 7.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 85.62K
- Price to Earnings (P/E)
- -4.9
- Beta (1Y)
- -0.30
- Revenue Growth
- ―
- EPS Growth
- 25.70%
- Country
- Canada
- Employees
- 5
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Marvel Biosciences Corp Business Overview & Revenue Model
Company Description
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, a...
Marvel Biosciences Corp Financial Statement Overview
Summary
Financial quality is very weak for a listed company: Marvel Biosciences has no revenue, persistent and material net losses, and a deeply negative equity position that has worsened over time, all of which point to a highly speculative balance sheet and ongoing dependence on external financing rather than internally generated cash. There are modest positives in that the latest TTM net loss and cash burn have narrowed versus FY 2025, indicating some cost control, but cash flows remain meaningfully negative and the asset base is small and shrinking, leaving limited flexibility if capital markets tighten.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
22Negative| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -385.42K | -547.37K | -302.02K | -887.52K | -1.38M | -613.10K |
| EBITDA | -1.92M | -1.94M | 1.22M | -2.25M | -2.55M | -1.25M |
| Net Income | -1.39M | -2.21M | -1,650 | -2.29M | -2.55M | -3.04M |
Balance Sheet | ||||||
| Total Assets | 471.73K | 326.71K | 491.31K | 672.39K | 913.54K | 2.47M |
| Cash, Cash Equivalents and Short-Term Investments | 434.80K | 128.85K | 345.77K | 556.62K | 593.21K | 2.39M |
| Total Debt | 1.40M | 2.31M | 1.71M | 1.00M | 0 | 0 |
| Total Liabilities | 3.21M | 4.33M | 3.32M | 2.39M | 718.00K | 112.48K |
| Stockholders Equity | -2.73M | -4.01M | -2.83M | -1.72M | 195.54K | 2.36M |
Cash Flow | ||||||
| Free Cash Flow | -778.84K | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Operating Cash Flow | -778.84K | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 381.57K |
| Financing Cash Flow | 824.62K | 933.41K | 968.64K | 1.30M | 394.00K | 3.16M |
Marvel Biosciences Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.13, and below the 200-day MA of 0.15, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 59.08 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MRVL.
Marvel Biosciences Corp Peers Comparison
Overall Rating
TSE:DRUG47Neutral
TSE:MRVL47Neutral
TSE:BETR41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | CAD 325.38M | -11.29 | -12.56% | ― | ― | -117.77% | |
| 47Neutral | CAD 8.19M | -4.87 | 39.05% | ― | ― | 25.70% | |
| 41Neutral | CAD 123.60M | -9.09 | 34.90% | ― | ― | -266.67% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:MRVL | Marvel Biosciences Corp | 0.13 | -0.04 | -25.71% | |
| TSE:BETR | Betterlife Pharma Inc. | 0.20 | 0.14 | 233.33% | |
| TSE:DRUG | Bright Minds Biosciences Inc. | 32.75 | -48.24 | -59.56% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% |
Marvel Biosciences Corp Corporate Events
Marvel Biosciences Extends Private Placement Access to Quebec Investors
PositiveMarvel Biosciences Corp. is a Calgary-based pre-clinical biotechnology company that redevelops existing, off-patent drugs into new synthetic derivatives aimed at treating neurological and non-neurological diseases. By focusing on targets such as the...
Marvel Biosciences’ MB-204 Shows Robust Efficacy in Fragile X Preclinical Study
PositiveMarvel Biosciences announced positive preclinical results showing its lead drug candidate MB-204 reversed behavioural and cognitive deficits in a Fragile X mouse model in a study run through the FRAXA Drug Validation Initiative. The compound produced...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jun 20, 2026
